Disclosed herein are compounds of formula 1 where the substituents are as defined herein. The compounds have activity as FXR binding and activity modulating compounds and are therefore intended for use in the treatment of conditions such as liver diseases, inflammatory bowel diseases, diabetes, obesity, myocardial infarction, stroke and hyperproliferative disorders.
